Biondvax Pharmaceuticals Ltd - ADR

NASDAQ:BVXV 3:59:53 PM EDT

1.17

-0.02 (-1.68%)

Other Pre-Announcement

Biondvax Receives Supportive Scientific Advice From The Paul Ehrlich Institute For Covid-19 Nanoab Development Plans

Published: 06/07/2022 13:32 GMT

Biondvax Pharmaceuticals Ltd - ADR (BVXV) - Biondvax Receives Supportive Scientific Advice From the Paul Ehrlich Institute (pei) for Covid-19 Nanoab Development Plans Including First-in-human Phase 1/2a Safety and Efficacy Clinical Trial.
Biondvax Pharmaceuticals Ltd - Plans to Initiate a First-in-human Phase 1/2a Clinical Trial in 2023.